Yixintang Pharmaceutical Group Co., Ltd.

SZSE:002727 Rapport sur les actions

Capitalisation boursière : CN¥8.0b

Yixintang Pharmaceutical Group Croissance future

Future contrôle des critères 3/6

Yixintang Pharmaceutical Group devrait augmenter ses bénéfices et son chiffre d'affaires de 45.8% et de 13.2% par an respectivement. Le BPA devrait croître de de 45.7% par an. Le rendement des capitaux propres devrait être 11.6% dans 3 ans.

Informations clés

45.8%

Taux de croissance des bénéfices

45.7%

Taux de croissance du BPA

Consumer Retailing croissance des bénéfices42.0%
Taux de croissance des recettes13.2%
Rendement futur des capitaux propres11.6%
Couverture par les analystes

Good

Dernière mise à jour19 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively

Nov 22
Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively

Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Nov 06
Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Sep 25
Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Jul 15
These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Jun 29
Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Jun 13
Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Jun 13
Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

May 27
Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

May 03
Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Apr 15
Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Mar 06
Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Prévisions de croissance des bénéfices et des revenus

SZSE:002727 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202624,6889371,1801,83911
12/31/202521,3747901,1192,00312
12/31/202418,3964498981,1238
9/30/202418,1571561,7622,015N/A
6/30/202418,0103272,0862,355N/A
3/31/202418,0445521,9852,269N/A
12/31/202317,3805491,8622,115N/A
9/30/202318,2191,0191,9712,361N/A
6/30/202318,1421,0962,2342,553N/A
3/31/202317,8721,0702,4022,733N/A
1/1/202317,4321,0102,1482,497N/A
9/30/202216,1158352,1252,509N/A
6/30/202215,8518161,5371,947N/A
3/31/202215,1548401,2951,668N/A
1/1/202214,5879221,4001,792N/A
9/30/202113,9169508151,120N/A
6/30/202113,329897610928N/A
3/31/202112,998846690988N/A
12/31/202012,6567907531,033N/A
9/30/202012,0567248271,023N/A
6/30/202011,4486831,0771,257N/A
3/31/202010,9786339841,185N/A
12/31/201910,479604776983N/A
9/30/201910,2195878381,017N/A
6/30/20199,945566719892N/A
3/31/20199,585565828988N/A
1/1/20199,176521480636N/A
9/30/20188,768525481619N/A
6/30/20188,391499N/A579N/A
3/31/20188,116457N/A330N/A
12/31/20177,751423N/A391N/A
9/30/20177,316386N/A166N/A
6/30/20176,949373N/A44N/A
3/31/20176,584345N/A134N/A
12/31/20166,249353N/A193N/A
9/30/20165,971379N/A124N/A
6/30/20165,774369N/A220N/A
3/31/20165,600361N/A163N/A
12/31/20155,321346N/A187N/A
9/30/20155,080323N/A234N/A
6/30/20154,854314N/A58N/A
3/31/20154,589310N/A34N/A
12/31/20144,428297N/A176N/A
9/30/20144,236292N/A211N/A
6/30/20143,995279N/A228N/A
3/31/20143,792253N/A284N/A
12/31/20133,547241N/A228N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 002727 ( 45.8% par an) est supérieure au taux d'épargne ( 2.8% ).

Bénéfices vs marché: Les bénéfices de 002727 ( 45.8% par an) devraient croître plus rapidement que le marché CN ( 26.1% par an).

Croissance élevée des bénéfices: Les bénéfices de 002727 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 002727 ( 13.2% par an) devrait croître plus lentement que le marché de CN ( 13.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 002727 ( 13.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 002727 devrait être faible dans 3 ans ( 11.6 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y